SCHEMBL676265

SCHEMBL676265

CCCC#Cc1ccc2c(c1)c1c(Cl)ccnc1n2S(=O)(=O)c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 8/20 0.35
MMP13 P45452 1/20 0.34
DCTPP1 Q9H773 1/20 0.33
HTR6 P50406 3/20 0.33
ENPP3 O14638 1/20 0.33
ENPP1 P22413 1/20 0.33
PTGDR Q13258 1/20 0.32
PAX8 Q06710 2/20 0.32
PIK3C3 Q8NEB9 1/20 0.32
GRM4 Q14833 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
PKM P14618 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL676525 0.87 GRM4 (0.39) PTGDR2ENPP3ENPP1GRM4KDM4E
SCHEMBL675233 0.83 HTR6 (0.36) PTGDR2MMP13HTR6PTGDRPAX8
SCHEMBL676233 0.82 SRC (0.34) PTGDR2MMP13DCTPP1HTR6PTGDR
SCHEMBL676809 0.79 PAX8 (0.40) HTR6ENPP3ENPP1PAX8NPC1
SCHEMBL674634 0.78 NPC1 (0.46) HTR6ENPP3ENPP1GRM4NPC1
SCHEMBL3662668 0.77 HTR6 (0.42) PTGDR2HTR6ENPP3ENPP1KDM4E
SCHEMBL675382 0.77 HTR6 (0.43) PTGDR2HTR6ENPP3ENPP1KDM4E
SCHEMBL675465 0.74 IP6K1 (0.38) PTGDR2HTR6ENPP3ENPP1KDM4E
SCHEMBL678731 0.74 IP6K1 (0.38) PTGDR2HTR6ENPP3ENPP1KDM4E
SCHEMBL675896 0.74 SRC (0.40) PTGDR2HTR6ENPP3ENPP1PIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
WO-2010025872-A2 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2010-03-11 WO disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 PTGDR2 3291/4885MMP13 3232/4885DCTPP1 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.